Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Jerill Thorpe | Researchclopedia

Back to researchers

Jerill Thorpe

Bristol-Myers Squibb (United States)ORCID

38

Works

1,296

Citations

14

h-index

17

i10-index

Research Topics

CAR-T cell therapy research T-cell and B-cell Immunology Chronic Lymphocytic Leukemia Research

Affiliations

Translational Research Institute2018–2018

Virginia Mason Medical Center2017–2024

Bristol-Myers Squibb (Germany)2023–2023

Bristol-Myers Squibb (United States)2020–2026

Juno Therapeutics (Germany)2019–2019

Top Works

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

S. Alice Long,Jerill Thorpe,et al.

2016243 citations

Immune Cell Function and Interaction

Diabetes and associated disorders

Comparison of commercial kits for detection of cryptococcal antigen

David C. Tanner,Melvin P. Weinstein,et al.

1994238 citations

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal,Daanish Hoda,et al.

2022223 citations

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi,Jacob D. Soumerai,et al.

2021118 citations

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes

S. Alice Long,Jerill Thorpe,et al.

201782 citations

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)

Lisa K. McNeil,Leah Price,et al.

201364 citations

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda,Kathleen Dorritie,et al.

202053 citations

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa,Shaji Kumar,et al.

202238 citations

Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype

James D. Lord,S. Alice Long,et al.

201833 citations